# Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

Study · id `cardio:ct-nct06797401` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06797401](<https://clinicaltrials.gov/study/NCT06797401>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06797401

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06797401. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06797401, source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-01-28 (actual) (ClinicalTrials.gov record NCT06797401, source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT06797401, source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT06797401, source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)
- Countries: Poland; Sweden (ClinicalTrials.gov record NCT06797401, source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06797401-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
- Condition: Dyslipidemias
- Intervention (Drug): RBD5044
- Intervention (Drug): Placebo
- Lead sponsor: Ribocure Pharmaceuticals AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Ribocure Pharmaceuticals AB (`cardio:org-ribocure-pharmaceuticals-ab`)

## Provenance

Content hash: cb66e318f61062eed07306a9e8dbbe8cd6e3731fea62f842f6fe83455c54b1a1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
